Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
MFN Policy Effectiveness in Countering Freeloading Claims
The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing by claiming it surrenders to foreign freeloading. This argument assumes manufacturers cannot negotiate better prices abroad due to socialist policies, take-it-or-leave-it propositions, and EU cartel accusations. However, evidence from the Trump administration’s 2025 executive order showcases MFN policy effectiveness as a market-leveraging tool, with voluntary deals from Pfizer, Eli Lilly, AstraZeneca, and others delivering MFN-level pricing for Medicaid, new launches, and direct-to-consumer channels via TrumpRx.gov—in exchange for tariff relief and U.S. manufacturing commitments—yielding billions in projected savings. Thus, MFN incentivizes higher foreign prices, as seen in Eli Lilly’s 170% UK list price increase for Mounjaro in 2025, without import controls or retaliation risks, since foreign governments rely on U.S.-driven innovation.
Exposing Access Myths
A core claim is that MFN would depress innovation and cause shortages by hindering recovery of high R&D costs—citing $2.6 billion average per drug, 11.5-15 years development, and low success rates (0.05% from screening to trials, 12% clinical approval)—while noting U.S. access to 90% of 2011-2018 new substances versus lower rates abroad (UK 60%, Japan 50%). This ignores that “access” metrics track launch timing, not utilization; U.S. high prices create barriers like deductibles and non-adherence, unlike peer nations’ post-launch affordability.
Shielding Biotech Edge from China’s Surge
The letter warns MFN would hand U.S. biotech leadership to China, citing ITIF data on China’s clinical trial doubling to 6,497 by 2021, oncology trial growth (+146%), pharma output share (24.2%), biotech patents (+720% to 1,920), and venture capital share (18.9%). U.S. strengths in IP, NIH research, and capital markets prevail, as MFN reallocates global R&D burdens fairly—the U.S. funds 70-75% of profits despite 5% world population. Industry R&D at 17-27% of revenues (higher in the U.S.) endures amid marketing and profit shifts, ensuring competitiveness.
Locking in Savings and Innovation Gains
The letter pushes free-market reforms and diplomacy, ignoring monopsony distortions and failed talks, while misframing MFN as socialist importation despite its role securing best terms for single-source brands in high-income OECD nations. Benefits include billions in Medicaid and taxpayer savings for expanded R&D credits; pricing aligns U.S. markups (3-4x OECD averages post-rebates) with benchmarks, improving adherence and outcomes without eroding incentives. Codification ensures policy certainty, secures 2025 gains like 80-85% direct-to-consumer discounts for diabetes and oncology drugs, and advances America First by ending subsidies to wealthy allies, boosting U.S. manufacturing, patient access, fiscal health, and pharma innovation leadership.
Unmasking Coordinated Industry Influence
Many of the letter’s most prominent signatories and its organizer, Americans for Tax Reform, maintain longstanding financial and operational linkages to PhRMA, the pharmaceutical industry’s primary lobbying arm. Tax filings and investigative reports show the Council for Affordable Health Coverage receiving over $3 million in PhRMA grants (while being managed by a pharmaceutical lobbying firm), the Pacific Research Institute receiving more than $1 million, along with grants to the Competitive Enterprise Institute, 60 Plus Association, and others. This pattern reflects PhRMA’s established strategy of funding conservative and free-market voices to oppose drug-pricing reforms—providing important context that the coalition’s arguments, while ideologically framed, are amplified by groups with direct stakes in preserving the status quo of U.S. overpayment.
